比美替尼（MEK162）用于对化疗和激素治疗耐药的复发性低级别浆液性卵巢癌。
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.
作者信息
Han Chanhee, Bellone Stefania, Zammataro Luca, Schwartz Peter E, Santin Alessandro D
机构信息
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
出版信息
Gynecol Oncol Rep. 2018 May 24;25:41-44. doi: 10.1016/j.gore.2018.05.011. eCollection 2018 Aug.
BACKGROUND
Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC.CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation experienced a dramatic clinical response to Binimetinib (MEK162), a mitogen-activated protein kinase (MEK) inhibitor, after failing multiple chemotherapy and hormonal treatments. An 81% reduction of target lesions by RECIST 1.1 over 31 months of response duration was confirmed with serial CT scans. Episodes of drug-related toxicity (pneumonitis) easily resolved without sequelae with the use of oral steroids.
CONCLUSION
Binimetinib may present a new treatment option for hormone- and chemotherapy-resistant LGSOC harboring mutations.
背景
晚期/复发性低级别浆液性卵巢癌（LGOSC）的管理通常具有挑战性。对于激素和化疗耐药的LGSOC，有效的治疗选择仍然有限。
病例
一名65岁复发性广泛性LGSOC女性，携带KRAS-G12V热点突变，在多次化疗和激素治疗失败后，对丝裂原活化蛋白激酶（MEK）抑制剂Binimetinib（MEK162）产生了显著的临床反应。通过连续CT扫描确认，在31个月的反应持续时间内，根据RECIST 1.1标准，靶病灶减少了81%。使用口服类固醇后，与药物相关的毒性反应（肺炎）发作很容易解决，且无后遗症。
结论
Binimetinib可能为携带突变的激素和化疗耐药LGSOC提供一种新的治疗选择。
Zotero 插件